We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Gracell Biotechnologies Inc | NASDAQ:GRCL | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.25 | 10.25 | 10.00 | 0 | 01:00:00 |
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:
Bristol Myers Squibb has agreed to acquire Karuna in a transaction valued at an estimated $14 billion. Under the agreement, shareholders of Karuna Therapeutics will be entitled to a payment of $330.00 per share in cash.
Daseke has agreed to be acquired by TFI International in a cash deal worth about $1.1 billion. Under the proposed transaction, Daseke shareholders will receive $8.30 per share in cash.
Bristol Myers Squibb has agreed to purchase RayzeBio in an all-cash deal valued at around $4.1 billion. In accordance with the merger agreement, RayzeBio shareholders are set to receive $62.50 per share in cash.
Under the proposed transaction AstraZeneca will purchase Gracell for $2.00 per ordinary share in cash, equivalent to $10.00 per Gracell ADS. A contingent value right of $0.30 per ordinary share (or $1.50 per Gracell ADS) in cash will be paid upon reaching a specific regulatory milestone.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
How to Get Involved:
Kuehn Law is dedicated to safeguarding shareholder interests. Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at justin@kuehn.law or call (833) 672-0814. Kuehn Law covers all case costs and does not charge its investor clients. Shareholders are advised to act promptly, as legal rights may be time-sensitive.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-krtx-dske-ryzb-and-grcl-investors-to-contact-law-firm-302028627.html
SOURCE Kuehn Law, PLLC
Copyright 2024 PR Newswire
1 Year Gracell Biotechnologies Chart |
1 Month Gracell Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions